Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2020 · 10-Q
Revenue$41.42M$41.42M+65.8% vs Q2 2019 Net Income$22.09M$22.09MN/M vs Q2 2019 EPS Diluted$1.32$1.32N/M vs Q2 2019 Operating Income$7,100,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin17.1%+33.7 pt vs Q2 2019
Net margin53.3%+111.0 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end